UQ, CEPI and CSL partner for COVID-19

• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate • …

Development of COVID-19 immunoglobulin commences

Plasma-derived therapeutic with potential to treat serious complications of COVID-19.

CSL Donates to Indonesian Relief Operations

CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunam…

CSL a Top 100 Company for Diversity & Inclusion

Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index

First SCIg Approved for CIDP

HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP

World Haemophilia Day

CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia

Patient Enrolled in CSL112 Clinical Trial

The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medical centers around the world.

Making Forbes’ Top Global Employers List

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth